Impact of carvedilol on the serum lipid profile

Annals of Pharmacotherapy

Volumn 42, Issue 4, 2008, Pages 564-571

  Sharp, Randall P ^a   Sirajuddin, Riaz ^b   Sharief, Imran M ^c  

^a SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

^b Heart Solutions of Oklahoma   (United States)

^c NONE

Author keywords

blockers; Carvedilol; Cholesterol; Hyperlipidemia

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LIPID; LOSARTAN; METOPROLOL TARTRATE; SOMATOSTATIN 14; THIAZIDE DIURETIC AGENT;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MEDLINE; PRIORITY JOURNAL; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CHOLESTEROL, HDL; HUMANS; LIPIDS; PROPANOLAMINES; TRIGLYCERIDES;

EID: 42049118510     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K447     Document Type: Review

References (22)

1. Package insert. Coreg (carvedilol). Research Triangle Park, NC: GlaxoSmithKline, January 2007.
2. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. DOI 10.1016/S0140-6736(03)13800-7
3. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90. DOI 10.1016/S0140-6736(00) 04560-8
4. National Institutes of Health, National Heart, Lung, and Blood Institute. JNC-7 express: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Publication no. 03-5223. Bethesda, MD: National Institutes of Health, December 2003.
5. Sarafidis PA, Bakris GL. Do the metabolic effects of β-blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens 2006;8:351-6. DOI 10.1111/j.1524-6175.2005.04679. x
6. Goto Y, Tamachi H, Fugawa Y, et al. Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc Pharmacol 1991;18(suppl 4):S45-50.
7. Uzunlulu M, Oguz A, Yorulmaz E. The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. Int Heart J 2006;47: 421-30. DOI 10.1536/ihj.47.42
8. Maqueda IG. Adenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis 1994;5: 909-18.
9. Zezina L, Vessby B, Larsson E, Backman U, Fellstrom B. Carvedilol treatment of kidney graft recipients with chronic rejection. Clin Transplant 1999;13:484-90. DOI 10.1034/j.1399-0012.1999.130608.x
10. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 2004;292:2227-36. DOI 10.1001/jama.292.18.2227
11. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007;20:777-83.
12. Weidmann P, De Courten M, Ferrari P. Effect of diuretics on the plasma lipid profile. Eur Heart J 1992;13(suppl):61-7.
13. Ames R. Hyperlipidemia of diuretic therapy. Arch Mal Coeur 1998; 91(suppl):23-7.
14. Package insert. Toprol XL (metoprolol succinate). Wilmington, DE: AstraZeneca, July 2007.
15. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med 1997;126:955-9.
16. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995;12:212-21.
17. Langdon CG, Baxter GA, Young PH. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1991;18(suppl 4):S51-6.
18. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens 2006;8:634-41. DOI 10.1111/j.1524-6175.2006.05504.x
19. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993;45:95-100. DOI 10.1007/BF00315487
20. Seguchi H, Nakamura H, Aosaki N, Homma Y, Mikami Y, Takashi S. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol 1990;38(suppl 2):S139-42.
21. Lithell H, Andersson PE. Metabolic effects of carvedilol in hypertensive patients. Eur J Clin Pharmacol 1997;52:13-7. DOI 10.1007/s002280050242
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000;283:1967-75.